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Abstract. – OBJECTIVE: The aim of this
study was to evaluate the accuracy of unen-
hanced whole-body MRI, including whole-body
Diffusion Weighted Imaging (DWI), used as a di-
agnostic modality to detect pathologic lymph
nodes and skeletal metastases in patients with
prostate cancer (PCa) undergoing restaging af-
ter primary treatment.
PATIENTS AND METHODS: 152 male patients
with biochemical recurrence after radical prosta-
tectomy (RP) or external beam radiation therapy
(EBRT) underwent MRI at a 1.5 Tesla magnet with
whole spinal sagittal T2-weighted, sagittal T1-
weighted, sagittal STIR images, axial T1 and T2-
weighted and STIR images of the pelvis and
whole-body. 18Fcholine-PET/CT exam was used
as the reference standard.
RESULTS: MRI protocol including whole-body
combined T1-weighted+T2-weighted+STIR+DWI
showed a sensitivity (Se) of 99%, a specificity
(Spe) of 98%, a positive predictive value (PPV) of
98%, a negative predictive value (NPV) of 96%,
an accuracy of 98% and an area under the re-
ceiver operating characteristic curve (AUC) of
0.971 for identification of bone metastatic lesion.
The same protocol, displayed a Se of 98%, a Spe
of 99%, a PPV of 97%, a NPV of 98%, an accura-
cy of 98 % and an AUC of 0.960 in the detection
of pathologic lymph nodes.
CONCLUSIONS: Unenhanced whole-body MRI,
including whole-body-DWI, is an accurate and
cost-effective diagnostic tool which is able to
detect lymph node involvement and bone metas-
tases in patients with biochemically recurrent
PCa after RP or EBRT.Thanks to its lack of ioniz-
ing radiation, excellent soft tissue contrast, high
spatial resolution, no need of contrast agent,
high Se and Spe, it could play a role in the
restaging procedure of such patients.
Key Words:
Diffusion magnetic resonance imaging, Prostate
cancer, Restaging, 11C-choline, 18F-fluorocholine,
Positron emission tomography/computed tomogra-
phy (PET/CT).
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Introduction
Prostate cancer (PCa) is second only to lung
cancer as a cause of cancer mortality among men
in western countries1 and accounts for one-third
of all deaths from cancer2,3. Relapse after primary
treatment, radical prostatectomy (RP) or radia-
tion treatment (RT), is still a significant due to its
relatively high frequency4. At present, the diag-
nosis of PCa recurrence is based mainly on rising
prostate-specific antigen (PSA) serum values and
it is named biochemical recurrence (BR)5. Once
BR is discovered, the next step is to distinguish
local recurrence from systemic disease in order
to plan the most appropriate treatment. In this
setting, diagnostic imaging plays an important
role in differentiating local relapse from metasta-
tic disease. Currently, an increasing number of
studies have been proposing multiparametric-
MRI as the most useful tool in the diagnostic
process of locally recurrent PCa after RP or RT.
On the other hand choline-PET/CT is the most
accurate diagnostic technique for the identifica-
tion of pathologic lymph nodes and bone metas-
tases6,7.
Nowadays, there is an increasingly growing
interest in the use of unenhanced MRI because
there are compelling clinical and pharmaceutical
needs to move towards an ideal whole-body
imaging evaluation by using techniques that
avoid radiation exposure.
In this contest, the aim of this study was to
evaluate the accuracy of an unenhanced whole-
body MRI protocol, including whole-body
DWI, in the detection of lymph node involve-
ment and skeletal metastases in patients with
PCa undergoing restaging after primary treat-
ment, using 18F-choline PET/CT as the standard
of reference.
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Patients and Methods
Patient
This prospective study was approved by the
local Ethics Committee, and all patients gave
written informed consent for inclusion in the
study.
From September 2011 to January 2014, 152
consecutive male patients (age range 53-88
years) affected by PCa and treated with RP or ex-
ternal-beam RT (EBRT) were referred to our In-
stitution for unenhanced whole-body MRI.
Patients treated with RP were included if they
had:
1. Positive 18FCholine-PET/CT for skeletal
and/or lymph node metastases
2. Post-RP PSA increase ≥ 1.2 ng/mL
4. No adjuvant or neoadjuvant hormonal thera-
pies
5. Gleason score ≥ 7
Patients treated with EBRT were included if
they had:
1. Positive 18FCholine-PET/CT for skeletal
and/or lymph node metastases
2. Serum PSA ≥ 2 ng/mL and at least three PSA
measurements in the last 6 months
3. Gleason score ≥ 7
4. No adjuvant hormonal therapies
Within one week after a 18FCholine-PET/CT, a
whole-body unenhanced MRI exam was per-
formed. The patient population was divided into
two groups on the basis of treatment delivered.
Group A included 82 patients who underwent RP
and Group B included 70 patients treated with
EBRT.
Unenhanced Whole-body MRI
All 152 patients were examined using a com-
mercially available 1.5-Tesla scanner (Magnetom
Avanto, Siemens Medical Solutions, Erlangen,
Germany), equipped with phased-array head-
neck and an eight-channel surface coils. The
whole-body MRI protocol included the following
sequences.
Whole-spine sagittal T1-weighted turbo spin-
echo images (repetition time [TR]: 180 ms; echo
time [TE]: 10 ms; slice thickness: 4 mm; matrix:
177 × 256).
Whole spine sagittal T2-weighted turbo spin-
echo images (TR: 4500 ms; TE: 101 ms; slice
thickness: 5 mm; matrix: 256 × 256).
Whole body sagittal T2-weighted STIR im-
ages (TR: 4500 ms; TE: 55 ms; inversion time:
170 ms; slice thickness: 5 mm; matrix, 384 ×
265).
Axial T1-weighted turbo spin-echo (TR: 400
ms; TE: 10 ms; slice thickness: 5 mm; matrix:
320 × 224), axial T2-weighted turbo spin-echo
(TR: 4000 ms; TE: 122 ms; slice thickness: 5
mm; matrix: 320 × 256) and axial T2-weighted
STIR (TR: 3000 ms; TE: 97 ms; inversion time:
180 ms; slice thickness: 5 mm; matrix: 320 ×
192) of the pelvis.
Whole-body DWI was acquired with free
breathing and inversion recovery single-shot
spin-echo echo-planar sequences in four imaging
stations (TR: 9000 ms; TE: 68 ms; matrix 128 ×
128; number of signals averaged: 6, section
thickness/gap: 5 mm/0 mm; b values/mm2 50,
500 and 800 or 1000).
The total imaging time was 40 minutes.
18F-choline PET/CT Study
All patients underwent whole-body 18F-choline
PET–CT in 3 different institutions, each exam
being acquired with the same PET–CT scan (16-
slice computed tomography scanner) and the
same equipment. PET/CT studies were per-
formed using the same protocol for every patient,
using a hybrid PET/CT tomograph (Discovery
ST unit, General Electric Medical Systems,
Waukesha, WI, USA). The acquisition protocol
begins 60 min after intravenous injection of the
choline solution (IASOcholine ®, Graz-Seiers-
berg, Austria, mean 212.4± 9.6 MBq, range 123–
272MBq, median 194 MBq).
Image Interpretation
PET/CT and MR images (Figure 1) were re-
viewed during four reading sessions by two spe-
cialists. The first specialist had 5 years of exper-
tise in MRI interpretation and 1 month of exper-
tise in PET/CT exams; the second specialist had
15 years of expertise in interpretation of MRI
and 10 years of expertise in PET/CT exams inter-
pretation.
In the first evaluation session the specialists
assessed conventional T1-weighted (T1W), T2-
weighted (T2W) and STIR sequences indepen-
dently and blinded to clinical data. A bone lesion
was deemed to be a metastasis if it was of low
signal intensity on T1W images and of high or
intermediate signal intensity on T2W and STIR
images compared with the surrounding bone
marrow. Lymph nodes were assumed as malig-
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Figure 1. MR and 18Fcholine-PET images of a 68-year-old patient with biochemical failure (PSA serum value 2.6 ng/mL)
after radical prostatectomy for prostate cancer. Sagittal STIR (A), sagittal T2-weighted (B) and sagittal T1-weighted (C) im-
ages showing a metastatic lesion (white arrow) located at posterior aspect of T1 vertebral body which appears of high signal
intensity on STIR image, slightly hyperintense on T2-weighted image and of low signal intensity on T1-weighted image. Axial
DW image (D), axial PET-like DW image (E) obtained with reversal window and PET image (F) display the bone lesion
(white arrow) which appears of high signal intensity on DW images and shows avid choline uptake at PET scan.
nant if the short-axis diameter was elongated and
exceeded 10 mm or if they were rounded and the
diameter exceeded 8 mm. The readers disagreed
in only 3% (4 out of 152) of the MR scans. The
final diagnoses were reached by consensus.
In the second reading session the specialists re-
viewed DW images independently, blinded to clin-
ical data and unaware of conventional MRI re-
sults. A suspicious skeletal metastatic lesion was
defined, by a qualitative image analyses, as a focal
or patchy area with signal intensity higher than
that of the surrounding bone marrow on native
DW images and dark on ADC map. A pelvic
lymph node was considered to be pathologic if it
was bright on native DW images compared to the
background and appeared of low signal intensity
on ADC map. The quantitative image analyses
were not performed. Therefore, ADC values were
not measured for both bone lesions and suspicious
lymph nodes because an accurate cut-off value has
not yet been established to distinguish between
benign and malignant disease. The readers dis-
agreed in only 4% (5 out of 152) of the DWI-MR
scans. The final diagnoses were reached by con-
sensus and by the consultation of a third reader.
In the third reading session the specialists an-
alyzed PET/CT images independently and
blinded to MRI results. PET images were first
assessed visually using transaxial, sagittal and
coronal planes. Visual interpretation was used
as the main criterion to reach the final diagno-
sis. Any uptake higher than background was
considered as tissue suspicious of malignancy.
The SUVmax (maximum standardized uptake
values) was measured for each lesion, but it was
not used as the main criterion to reach the final
diagnosis because an accurate cut-off value has
not yet been established. A bone lesion was
counted as metastasis if it showed radiotracer
accumulation and if it could not be rated as a
benign process. Corresponding morphology da-
ta from low-dose CT were analyzed in the eval-
uation of focal tracer accumulation in the
PET/CT examination. Lymph node involvement
was considered pathologic if a lymph node
showed a higher than background uptake of the
radiotracer. The readers disagreed in only 7%
(10 out of 152) of the choline PET/CT scans.
The final diagnoses were reached by consensus
and by the opinion of a third reader.
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In the last evaluating session the readers com-
pared, in consensus, PET/CT scans, conventional
MR images and DW images of each patient, be-
ing aware of clinical data.
Statistical Analysis
Statistical data analysis was performed using
software MedCalc for Windows. Sensitivity (Se),
specificity (Spe), positive predictive value (PPV),
negative predictive value (NPV) and accuracy of
whole-body unenhanced MRI were calculated on
a per-lesion basis analyses. Receiver operating
characteristic (ROC) curves were generated to
compare the ability of various MR protocols to
detect skeletal metastases and pathologic lymph
nodes. 18Fcholine-PET/CT was considered the
reference standard for both pathologic bone le-
sions and suspicious nodes. Statistically signi-
ficative difference between different MRI proto-
cols and the standard of reference was assessed
by means of the chi-square test (the significance
was set at p ≤ 0.05).
Results
The results of bone metastases identification
are summarized in Table I and Figure 2. There
was no statistically significant discordance be-
tween T1W+T2W+STIR+DWI and T1W+
T2W+DWI imaging protocols compared with
each other or with the standard of reference
(T1W+T2W+STIR+DWI vs. T1W+T2W+DWI,
p = 0.27; T1W+T2W+STIR+DWI vs. reference,
p = 0.25; T1W+T2W+DWI vs. reference, p =
0.23). A statistically significant discordance was
observed between T1W+T2W+STIR vs.
T1W+T2W+STIR+DWI p = 0.0469, T1W+
T2W+STIR vs. T1W+T2W+DWI p = 0.0436,
T1W+T2W+STIR vs. reference p = 0.0326,
STIR+DWI vs. T1W+T2W+STIR+DWI p =
0.0395, STIR+DWI vs. T1W+T2W+DWI p =
0.0274, STIR+DWI vs. reference p = 0.0256,
DWI vs. T1W+T2W+STIR+DWI p = 0.0349,
DWI vs. T1W+T2W+DWI p = 0.0346 and DWI
vs. reference p = 0.0196.
The results of pathologic lymph nodes identifi-
cation are summarized in Table II and Figure 2.
A statistically significant discordance was ob-
served between T1W+T2W+STIR vs. T1W+
T2W+STIR+DWI p = 0.0412, T1W+T2W+
STIR vs. T1W+T2W+DWI p = 0.0358, T1W+
T2W+STIR vs. STIR+DWI p = 0.0468,
T1W+T2W+STIR vs. DWI p = 0.0417, T1W+
T2W+STIR vs. reference p = 0.0264.
Discussion
Recently, multiparametric-MRI has been pro-
posed as the most useful tool in the diagnostic
process of local relapse of PCa after RP and after
RT.
PET/CT using 11C or 18F-labeled choline com-
pounds, on the other hand, is the most promising
whole-body imaging modality for detection of
lymph node involvement and bone metastases
during restaging of biochemically recurrent PCa
after RP or EBRT, with a high Se, Spe and accu-
racy8,9.
Currently, there are compelling clinical and
pharmaceutical needs to move towards an ideal
whole-body evaluation of cancer burden by using
imaging techniques that avoid radiation exposure
and fulfill, at the same time, some essential pre-
requisites such as accuracy, availability, repro-
ducibility, cost effectiveness and efficiency10.
DW-MRI seems to fulfill these requirements, be-
cause no ionizing radiation is administered and
no intravenous injection of isotopes or any con-
trast medium is necessary. DWI is based on an
echo-planar sequence and depicts the diffusivity
of water molecules along the three space direc-
MRI sequences Se Spe PPV NPV Accuracy AUC
T1W+T2W+STIR+DWI 99% 98% 98% 96% 98% 0.971
T1W+T2W+DWI 99% 97% 96% 95% 96% 0.943
T1W+T2W+STIR 86% 98% 95% 84% 89% 0.871
STIR+DWI 83% 96% 93% 82% 87% 0.771
DWI 98% 82% 83% 93% 84% 0.700
Table I.MRI results in detecting bone metastases.
Se: sensitivity; Spe: specificity; PPV: positive predictive value; NPV: negative predictive value; AUC: area under the receiver
operating characteristic curves.
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tions within the tissue. It provides qualitative and
quantitative information reflecting tissue cellular-
ity and cell membrane integrity and, thus, com-
plements morphologic information obtained with
conventional MRI11.
Recent technologic advances have enabled the
development of whole-body examinations with
DWI. Most modern 1.5- or 3-Tesla MRI units
with echo-planar and parallel imaging capabili-
ties and with high-performance gradients and
phased-array multichannel surface coils can be
used to perform whole-body DWI in reasonably
short data-acquisition times12.
With this background, the purpose of this
work was to evaluate the accuracy of a whole-
body unenhanced MRI protocol including whole-
body DWI in the detection of pathologic lymph
nodes and skeletal metastases in patients with
PCa who undergo restaging after RP or RT. MRI
was compared to 18F-choline PET/CT, used as the
standard of reference. From September 2011 to
January 2014, we studied a large number of pa-
tients (152 consecutive male patients) with BR.
Unenhanced whole-body MRI protocol including
T1W+T2W+STIR+DWI showed a high Se, Spe
and accuracy in detecting bone metastases and
lymph node involvement, almost comparable to
18F-choline PET/CT in both group A and group B
patients. We hypothesized that the overall accura-
cy of 18F-choline PET/CT imaging is moderately
superior to that of whole-body MRI because
DWI can suffer several artifacts, such as: intrin-
sic distortion artifacts, distortion artifacts in the
pelvic region, gas pockets, magnetic susceptibili-
ty artifacts due to hip replacements and motion
artifacts. We noticed that whole-body DWI, used
as single imaging modality, seemed to be a very
sensitive but rather unspecific modality for the
detection of bone metastases; this should be re-
lated to the false-positive findings that could be
encountered with this technique. Causes of false-
ly-positive high bone marrow signal intensity on
Figure 2. Receiver operating characteristic (ROC) curve comparison for each technique in the detection of bone metastatic le-
sions (left ROC curves) and pathologic lymph nodes (right ROC curves). ROC curves for bone metastases show area under the
curve (AUC) for combined whole-body T1W+T2W+STIR+DWI, T1W+T2W+DWI, T1W+T2W+STIR, STIR+DWI and DWI.
ROC curves for pathologic lymph nodes show AUC for combined whole body T1W+T2W+STIR+DWI, T1W+T2W+DWI,
STIR+DWI, DWI and T1W+T2W+STIR.
MRI sequences Se Spe PPV NPV Accuracy AUC
TT1W+T2W+STIR+DWI 98% 99% 97% 98% 98% 0.960
T1W+T2W+DWI 97% 95% 94% 88% 97% 0.921
STIR+DWI 95% 92% 93% 91% 92% 0.895
DWI 93% 85% 89% 80% 87% 0.816
T1W+T2W+STIR 81% 87% 82% 89% 81% 0.658
Table II.MRI results in detecting pathologic lymph nodes.
Se: sensitivity; Spe: specificity; PPV: positive predictive value; NPV: negative predictive value; AUC: area under the receiver
operating characteristic curves.
DW images include bone marrow edema caused
by fracture, degenerative disease, bone infarc-
tion, infection, hemangioma, isolated islands of
red bone marrow within yellow marrow and T2
shine-through effect. Nevertheless, many of these
false-positive rises in signal intensity on DWI
images can be overcome by performing image
interpretations with ADC maps and conventional
images. Therefore, conventional imaging includ-
ing T1W, T2W and STIR sequences may im-
prove the specificity of DWI in detecting bone
metastases. In our study, the quantitative image
analyses was not performed; therefore, ADC val-
ues were not estimated for both bone lesions and
suspicious lymph nodes, because a) there is an
overlap in ADC values of benign and malignant
disease, b) the inconsistency of ADC cutoff val-
ues among different studies, and c) high observer
variability in defining regions of interest for mea-
surement of ADCs of small lesions13,14.
The main limitation of our study might seem to
be the imperfect reference standard used, as we
could not verify any of the metastases by biopsy
for ethical and logistic reasons. Nevertheless, this
is not of primary concern because the aim of our
study was not to survey the effective Se and Spe of
unenhanced whole-body-MRI in detecting patho-
logic lymph nodes and skeletal metastases in pa-
tients with biochemically recurrent PCa after RP
or EBRT. Our goal was to assess if MRI could be
considered comparable to 18F-choline PET/CT
which is up to now widely considered to be the
“state of the art” in the restaging procedure of
such patients.
Our latest practice highlights the diagnostic
power of unenhanced whole-body MRI including
whole-body DWI that can be considered to be al-
most comparable to 18F-choline PET/CT, which
has been assumed to be, up to now, the most reli-
able diagnostic modality in restaging patients
with PCa. Therefore, our data could pave the way
to the possibility of using unenhanced whole-
body MRI including whole-body DWI as an al-
ternative to 18F-choline PET/CT for follow up af-
ter RP and RT, with a high Se, Spe and accuracy
in detecting bone metastases and lymph node in-
volvement. Besides, there are other reasons that
foster the possibility of using unenhanced whole-
body MRI including whole-body DWI as an al-
ternative to 18F-choline PET/CT: its acceptable
acquisition time, its repeatability which is ab-
solutely superior to that of a PET/CT exam, and
the absence of complications due to intravenous
administration of contrast medium. Our findings
show the potential of unenhanced whole-body
MRI including whole-body DWI as a feasible
and very useful tool in detecting bone and lymph
node metastases, owing to its diagnostic accura-
cy. Unenhanced whole-body MRI including
whole-body DWI can be, therefore, proposed ei-
ther as a further imaging study or as a reliable al-
ternative to 18F-choline PET/CT in restaging PCa
patients.
Conclusions
Unenhanced whole-body MRI including
whole-body DWI could play a role as part of
restaging of patients with biochemically recur-
rent PCa after RP or EBRT.
MRI has several advantages such as the lack
of ionizing radiation, excellent soft tissue con-
trast, high spatial resolution, and no need of con-
trast agent. Lastly, its high Se and Spe, which are
similar to that of 18F-choline PET/CT, make it a
promising accurate and cost-effective diagnostic
tool for detection of pathologic lymph nodes and
bone metastases in such patients.
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